Table I.
Examination | Representative effective dose value (mSv) | Range of reported effective dose values (mSv) | Administered activity (MBq) |
---|---|---|---|
Chest X-ray posteroanterior and lateral | 0.1 | 0.05–0.24 | N/A |
Diagnostic invasive coronary angiogram | 7 | 2–16 | N/A |
Coronary CT angiogram | |||
64-slice multidetector, retrospective gating | 12 | 9–19 | N/A |
64-slice multidetector, reduced tube voltage (100 kVp) | 6 | 3–8 | N/A |
64-slice multidetector, prospective triggering | 3 | 2–4 | N/A |
Dual-source high pitch | <1 | <1 | N/A |
264 or 320 multidetector row CT | 4 | 2–8 | N/A |
Nuclear medicine studies | |||
Myocardial perfusion | |||
Sestamibi (1-day) stress/rest | 12 | N/A | 1480 |
Tetrofosmin (1-day) stress/rest | 10 | N/A | 1480 |
Thallium stress/redistribution | 29 | N/A | 130 |
Rubidium-82 rest/stress | 10 | N/A | 2960 |
Myocardial viability | |||
PET F-18 FDG | 14 | N/A | 740 |
Thallium stress/reinjection | 41 | N/A | 185 |
CT, computed tomography; FDG, fluorodeoxyglucose; N/A, not applicable; PET, positron emission photography. This table has been adapted from a previous study (58).